Navigation Links
Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer

Freeze-drying of biopharmaceuticals to be available at the Company’s Mississauga, Ontario facility.

Toronto, ON (PRWEB) November 8, 2009 -- Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has taken delivery of a commercial scale pharmaceutical grade freeze dryer and expects to make commercial scale freeze drying (lyophilization) available for contract manufacturing of biopharmaceuticals early in 2010.

Lyophilization is used to convert biopharmaceuticals that are manufactured in an unstable liquid format into a stable, dry powder that can be reconstituted to a liquid format for administration to patients. Lyophilized forms of these life-saving products are more easily handled and stable than their liquid forms and therefore lyophilization is commonly used in the manufacture of these products.

“Commercial scale lyophilization is not readily available in Canada,” said Thomas Wellner. “The addition of a commercial-scale lyophilizer to the clinical scale capability Therapure Biopharma has now will significantly enhance the value we will bring to Therapure clients.”

Installation of the lyophilizer began last week and is expected to be completed in December. Following the installation, the Company will complete the extensive validation process required to achieve current Good Manufacturing Practices (cGMP) status. Therapure Biopharma will begin offering commercial-scale lyophilization services from its Health Canada commercially licensed plant early in 2010.

About Therapure Biopharma:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit:

Media Contacts:
Thomas Wellner, President and CEO
Therapure Biopharma Inc.
+1 905-286-6204

# # #

Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
2. Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top
3. aTyr Pharma to Present at Japan Biopharma Partnering Conference
4. Keryx Biopharmaceuticals, Inc. to Hold Investor/Analyst Day Tomorrow
5. DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines
6. PDL BioPharma Announces Conversion Rate Adjustment for Its 2.75% Convertible Subordinated Notes Due August 16, 2023
7. Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
8. UK's Newcastle University Introduces First-Ever Biopharmaceutical Engineering Doctorate Program
9. PDL BioPharma to Present at BioCentury Newsmakers Conference on September 16, 2009
10. Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma
11. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
Post Your Comments:
(Date:11/24/2015)... ... ... Charitable giving is at its peak during the holidays. In fact, ... the year totalling over $358 billion in 2014. With more than 1.5 million ... individuals who want to “give back” during the holidays. , “With so many charities ...
(Date:11/24/2015)... ... November 24, 2015 , ... In an article ... variables that determine which patients are or are not eligible for bariatric surgery. The ... BMI over 40, are more than 100 pounds overweight, or have a BMI of ...
(Date:11/24/2015)... ... ... DMG Productions announced that they will feature Aphria, Inc., in an upcoming episode ... and show times TBA. , Aphria, Inc., is a publicly traded company incorporated under ... medical marijuana pursuant to the Marijuana for Medical Purposes Regulations (the “MMPR”). , Aphria ...
(Date:11/24/2015)... ... ... Preparing for the LDT Regulation:, CLIA Won’t Satisfy the FDA, Dec. ... has long asserted that design and manufacture of Laboratory Developed Tests (LDTs) falls under ... the device regulations. , Come up short in an inspection and the FDA can ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... organization will waive paid entry and parking fees at several of their most ... Mountain in Great Barrington in support of REI’s Black Friday #OptOutside Campaign. The ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... -- Today AVACEN Medical announced the issue of United States patent No. 9,192,509 ... This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods of ... Photo - ... ... ...
(Date:11/25/2015)... -- Endo International plc (NASDAQ: ENDP ) (TSX: ENL) ... CEO, will discuss corporate updates at the 27 th ... on Wednesday, December 2, 2015 at 1 p.m. ... and then the link to the event. Participants should allow ... visit the site and download any streaming media software needed ...
(Date:11/25/2015)... November 25, 2015 --> ... blood glucose devices was valued at $11,171.1 million in ... CAGR of 5.7% during 2015 - 2022. The global ... increasing prevalence of diabetes. In addition, the increase in ... also contributing to the growth of the market. Furthermore, ...
Breaking Medicine Technology: